[Skip to Content]
[Skip to Content Landing]
October 1982

Commentary: Sulfoxone (Diasone) in the Treatment of Dermatitis Herpetiformis

Author Affiliations

From the Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Arch Dermatol. 1982;118(10):809-812. doi:10.1001/archderm.1982.01650220113016

Until introduction of the sulfonamides, arsenic, in the form of potassium arsenite (Fowler's) solution or as an arsenic trioxide and black pepper preparation (Asiatic pills), had been the major and most effective form of therapy for dermatitis herpetiformis. Unfortunately, more than 25% of patients given arsenic experienced arsenical keratoses, pigmentation, or other manifestations of arsenism.1 Many other forms of therapy had been tried, including x-rays, UV light, autohemotherapy, intravenous sodium cacodylate, sedatives, cowpox vaccinations, and even autogenous vaccines from the stool (from Streptococcus viridans and nonhemolytic Escherichia coli), each without much benefit. Thus, when Costello2 reported the effective use of sulfapyridine therapy in a patient with dermatitis herpetiformis, which he believed was caused by a bacterial allergy, it was enthusiastically accepted. Other sulfonamides (primarily sulfanilamide) had been tried, with only variable success. For years after the introduction of sulfapyridine until today, many believed that it was the pyridine

First Page Preview View Large
First page PDF preview
First page PDF preview